Ablynx: PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR

Ablynx: PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")  REGULATED INFORMATION  GHENT, Belgium, 8 July 2014 -Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from FMR LLC.  The above legal entity informed that  it has been granted discretionary  power  to vote for more than 3% of Ablynx' voting rights, as it shall exercise voting rights incorporated in 1,810,500 Ablynx  shares, which represent 3.35% of  the  current 53,991,659 outstanding shares of Ablynx.  Such voting rights shall be exercised by FMR LLC, which controls the following companies acting  as  fund manager  for  various undertakings  for  collective  investment, that hold a participation in Ablynx shares: Fidelity Management  &  Research Company,  Pyramis Global  Advisors LLC  and Pyramis  Global  Advisors  Trust Company.  Full versions of all transparency  notifications are available on the  website  of Ablynx, under the section Investors.  About Ablynx  Ablynx is a biopharmaceutical company engaged in the discovery and development of NanobodiesĀ®, a novel class  of therapeutic proteins based on  single-domain  antibody  fragments,  for  a  range  of  serious  human  diseases,   including  inflammation, haematology, oncology and pulmonary disease. Today, the  Company  has more than 30 programmes in  the pipeline and seven Nanobodies in  clinical  development. Ablynx  has  on-going  research  collaborations  and  significant  partnerships with major pharmaceutical companies including AbbVie,  Boehringer  Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.  Voor bijkomende informatie, gelieve contact op te nemen met  Ablynx:  Dr Edwin Moses Gedelegeerd Bestuurder t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 /  +32 (0)473 39 50 68 e: edwin.moses@ablynx.com  Marieke Vermeersch Associate Director Investor Relations t: +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e: marieke.vermeersch@ablynx.com Volg ons op Twitter @AblynxABLX  Ablynx media relaties Consilium Strategic Communications:  Mary-Jane Elliott, Amber Bielecka, Lindsey Neville t: +44 203 709 5700 e: ablynx@consilium-comms.com  pdf format of the press release  ------------------------------------------------------------------------------  This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Ablynx via Globenewswire HUG#1818479  
Press spacebar to pause and continue. Press esc to stop.